217 related articles for article (PubMed ID: 23569008)
1. ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells.
Zheng C; Jiao X; Jiang Y; Sun S
J Int Med Res; 2013 Apr; 41(2):300-6. PubMed ID: 23569008
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
Fryer RA; Barlett B; Galustian C; Dalgleish AG
Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196
[TBL] [Abstract][Full Text] [Related]
4. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
5. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
Wang M; Lu X; Dong X; Hao F; Liu Z; Ni G; Chen D
World J Surg Oncol; 2015 Feb; 13():66. PubMed ID: 25880226
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Yokoi K; Fidler IJ
Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
[TBL] [Abstract][Full Text] [Related]
8. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.
Holcomb BK; Yip-Schneider MT; Waters JA; Beane JD; Crooks PA; Schmidt CM
J Gastrointest Surg; 2012 Jul; 16(7):1333-40. PubMed ID: 22618517
[TBL] [Abstract][Full Text] [Related]
9. RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.
Duxbury MS; Ito H; Benoit E; Waseem T; Ashley SW; Whang EE
Clin Cancer Res; 2005 May; 11(9):3433-8. PubMed ID: 15867245
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.
Tang Y; Liu F; Zheng C; Sun S; Jiang Y
J Exp Clin Cancer Res; 2012 Sep; 31(1):73. PubMed ID: 22967941
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
Ng SSW ; Tsao MS; Chow S; Hedley DW
Cancer Res; 2000 Oct; 60(19):5451-5. PubMed ID: 11034087
[TBL] [Abstract][Full Text] [Related]
12. Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells.
Amrutkar M; Aasrum M; Verbeke CS; Gladhaug IP
BMC Cancer; 2019 Jun; 19(1):596. PubMed ID: 31208372
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
Yip-Schneider MT; Schmidt CM
Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
15. ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
Su YH; Hsu TW; Chen HA; Su CM; Huang MT; Chuang TH; Leo Su J; Hsieh CL; Chiu CF
J Cell Physiol; 2021 Jun; 236(6):4420-4434. PubMed ID: 33184874
[TBL] [Abstract][Full Text] [Related]
16. ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.
Luk PP; Galettis P; Links M
Lung Cancer; 2011 Sep; 73(3):274-82. PubMed ID: 21277645
[TBL] [Abstract][Full Text] [Related]
17. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
18. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
Guo Q; Chen Y; Wu Y
Tumori; 2009; 95(6):796-803. PubMed ID: 20210246
[TBL] [Abstract][Full Text] [Related]
19. Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.
Simon PO; McDunn JE; Kashiwagi H; Chang K; Goedegebuure PS; Hotchkiss RS; Hawkins WG
Int J Cancer; 2009 Aug; 125(4):942-51. PubMed ID: 19405118
[TBL] [Abstract][Full Text] [Related]
20. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
Pham NA; Tsao MS; Cao P; Hedley DW
Pancreas; 2007 Oct; 35(3):e16-26. PubMed ID: 17895832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
